 phase II multi-institutional trial low-dose N- phosphonacetyl -L-aspartate high-dose short-term infusion treatment adenocarcinoma pancreas Southwest Oncology Group study Adenocarcinoma pancreas lethal malignancy chemotherapy little impact natural history disease PALA vivo vitro Twenty-seven patients intravenous push dose PALA hours infusion regimen partial response eligible patients response rate Toxicity severe toxic death patients Grade toxicity PALA schedule effective adenocarcinoma pancreas